TNFRSF8 and rheumatoid arthritis: In the current study, five of 21 RA patients with OIIA TNK-LPDs (24%) showed a lethal progressive clinical course within 13 months, having features of TFH+ PTCL, EBV+ CD4+ CD30+ large-cell PTCL-NOS, EBV− CD8+ sALCL, and sEBV+ CD8+ CD30+/− TCLs.